Exagen Inc. (NASDAQ:XGN) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET

Company Participants

Ryan Douglas - Investor Relations

Ron Rocca - President and Chief Executive Officer

Kamal Adawi - Chief Financial Officer

Conference Call Participants

Griffin Soriano - William Blair

Ross Osborn - Cantor Fitzgerald

Ryan Douglas

Good afternoon, and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended June 30th, 2022. The release is currently available on the company's website at www.exagen.com. Ron Rocca, President and Chief Executive Officer; Kamal Adawi, Chief Financial Officer; Mark Hazeltine, Chief Operating Officer, will host this afternoon's call.

Before we get started, I'd like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements.

All forward-looking statements, including, without limitation, statements regarding our business strategy and future financial and operating performance, including 2022 guidance, the impact of COVID-19 pandemic on our business, our current and future product offerings, and reimbursement and coverage are based upon current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please see our filings with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31st, 2021, and subsequent filings. The information provided in the conference call speaks only to the live broadcast today, August 4th, 2022.

Exagen disclaims any intention or obligation, except as required by law, to update or revise any information, financial projections or other forward-looking statements, whether because of new information, future events or otherwise.

I'll now turn the call over to Ron Rocca, President and CEO of Exagen.

Ron Rocca

Thanks, Ryan, and thank you to everyone joining the call. Today, I will discuss our Q2 business highlights and give updates on payers, our pipeline, the newly published CAPSTONE study and the initiation of our TiGER clinical experience study for RADR platform. I'll then hand the call over to Kamal, our CFO, for details on our financial results. As always, we appreciate your continued support of Exagen.